早期に診断されたSCID乳児のコンディショニング (CSIDE)
TCRαβ+/CD19+枯渇移植を受けた重度複合免疫不全症 (SCID) の乳児に対する低暴露対中暴露ブスルファンの無作為化試験: 一次免疫不全治療コンソーシアム (PIDTC) および小児血液および骨髄移植コンソーシアム (PBMTC) による第 II 相試験
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants.
The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. The exact regimen depends on the subtype of SCID the patient has. Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is completed, patients will be followed for 3 years. Approximately 9-18 months after the transplant, vaccinations will be administered, and a blood test measuring whether your child's body has responded to the vaccine will be collected.
調査の概要
詳細な説明
This is a prospective, multicenter, phase II, open-label study of two reduced busulfan dose levels in newborns identified at birth with SCID of appropriate genotype/phenotype and clinical status, undergoing either haploidentical related or well-matched unrelated donor TCRαβ+/CD19+ depleted HCT. Subjects will be enrolled on either of 2 strata according to genotype (defects of cytokine receptor function i.e. IL2RG or JAK3 and defects of receptor recombination i.e. RAG1 or RAG2). Thus up to 32 subjects on each of 2 strata or 64 subjects total would be enrolled over 4 years with 3 years follow-up.
Patients with IL2RG/JAK3 would be randomized to receive busulfan targeted either to cumulative exposure of 25-35 mg*h/L or 55-65 mg*h/L with Thymoglobulin. Patients with RAG1/2 would be randomized to receive busulfan targeted to cumulative exposure of 25-35 mg*h/L or 55-65 mg*h/L, in conjunction with fludarabine, thiotepa and Thymoglobulin. Safety/feasibility of the novel TCR αβ+/CD19+ depleted allogeneic HCT strategy will be monitored on an ongoing basis using stopping rules for lack of neutrophil engraftment and other important short-term toxicities.
Donor selection would be determined clinically at the discretion of the treating clinicians at each site. Pharmacokinetic monitoring of busulfan exposure will be performed per local practices at CLIA-certified laboratories. Patients will receive busulfan and pharmacokinetic measurement to individualize dosing. Time-concentration data of the initial dose and subsequent doses will be reviewed centrally (Dr. Janel Long-Boyle) using a cloud-based application (InsightRx) to guide dose adjustment in real-time (Long-Boyle, Chan, Keizer, 2017, ASBMT Tandem abstract accepted). Clinical and laboratory data will be collected at defined time points over 3 years and entered in an electronic data capture system using study-specific case report forms. These data will be used to measure the outcomes including the primary outcome (cAUC of busulfan that promotes humoral immune reconstitution at 2 years post HCT with acceptable regimen-related toxicity at 42 days post HCT) and secondary outcomes (the quality of donor cell engraftment and immune function achieved in B and T cell compartments and survival). Mechanistic studies supporting the exploratory endpoints will be conducted centrally in designated laboratories.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35294
- Univeristy of Alabama at Birmingham
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85016
- Mayo Clinic Arizona and Phoenix Children's Hospital
-
-
California
-
Los Angeles、California、アメリカ、90027
- Children's Hospital Los Angeles
-
Los Angeles、California、アメリカ、90095
- UCLA Center for Health Sciences
-
San Diego、California、アメリカ、92123
- Rady Children's Hospital, San Diego
-
San Francisco、California、アメリカ、94143
- University of California San Francisco Medical Center - Peds
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- University of Colorado - Children's Hospital
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- Children's National Medical Center
-
-
Florida
-
Gainesville、Florida、アメリカ、32610
- Shands HealthCare & University of Florida
-
Miami、Florida、アメリカ、33136
- University of Miami/Jackson Memorial Hospital
-
St. Petersburg、Florida、アメリカ、33701
- All Children's Hospital
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30329
- Children's Healthcare of Atlanta at Egleston
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- Comer Children's Hospital/University of Chicago Medicine
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70118
- Children's Hospital / LSUHSC
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- Dana Farber Cancer Institute - Peds
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- The University of Michigan
-
Grand Rapids、Michigan、アメリカ、49503
- Helen DeVos Children's
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- University of Minnesota Blood and Marrow Transplant Program - Pediatrics
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64108
- The Children's Mercy Hospitals and Clinics
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68198
- Nebraska Medicine
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601
- Hackensack University Medical Center
-
-
New York
-
New York、New York、アメリカ、10032
- Morgan Stanley Children's Hospital of New York-Presbyterian - Columbia University Medical Center
-
Queens、New York、アメリカ、11040
- Cohen Children's Medical Center
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28203
- Levine Children's Hospital
-
Durham、North Carolina、アメリカ、27705
- Duke University Medical Center; Pediatric Blood and Marrow Transplant
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45229
- Cincinnati Children's Hospital Medical Center
-
-
Oregon
-
Portland、Oregon、アメリカ、97239-3098
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- Children's Hospital of Philadelphia
-
Pittsburgh、Pennsylvania、アメリカ、15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt University Medical Center
-
-
Texas
-
Dallas、Texas、アメリカ、75235
- Children's Medical Center Dallas
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- Utah Blood and Marrow Transplant Program-Peds
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- Fred Hutchinson Cancer Center / Seattle Children's
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53792
- University of Wisconsin Hospital and Clinics
-
Milwaukee、Wisconsin、アメリカ、53226
- Children's Hospital of Wisconsin
-
-
-
-
Montreal
-
Montreal、Montreal、カナダ、QC
- Centre Hospitalier Universitaire Sainte-Justine
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 1E8
- The Hospital for Sick Children
-
-
Winnipeg
-
Winnipeg、Winnipeg、カナダ、MB
- Cancer Care Manitoba/University of Manitoba
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
1. Infants with SCID, either typical or leaky or Omenn syndrome.
-
Typical SCID is defined as either of the following
- Absence or very low number of T cells (CD3+ T cells <300/microliter AND no or very low T cell function (<10% of lower limit of normal) as measured by response to phytohemagglutinin OR
- Presence of maternally derived T cells
-
Leaky SCID is defined as the following
• Absence of maternally derived T cells
• AND either one or both of the following (i, ii): i) <50% of lower limit of normal T cell function as measured by response to PHA OR <30% of lower limit of normal T cell function as measured by response to CD3 ii) Absent or <10% of lower limit of normal proliferative responses to candida and tetanus toxoid antigens (must document post vaccination or exposure for this criterion to apply)
• AND at least two of the following (i through iii): i) CD3 T cells < 1500/microliter ii) >80% of CD3+ or CD4+ T cells are CD45RO+ AND/OR >80% of CD3+ or CD4+ T cells are CD62L negative AND/OR >50% of CD3+ or CD4+ T cells express HLA-DR (at < 4 years of age) AND/OR are oligoclonal T iii) Low TRECs and/or the percentage of CD4+/45RA+/CD31+ or CD4+/45RA+/CD62L+ cells is below the lower level of normal.
-
Omenn syndrome • Generalized skin rash
-
Maternal lymphocytes tested for and not detected.
-
>80% of CD3+ or CD4+ T cells are CD45RO+ AND/OR >80% of CD3+ or CD4+ T cells are CD62L negative AND/OR >50% of CD3+ or CD4+ T cells express HLA-DR (<2 years of age)
-
Absent or low (up to 30% lower limit of normal (LLN)) T cell proliferation to antigens (Candida, tetanus) to which the patient has been exposed IF: Proliferation to antigen was not performed, but at least 4 of the following 8 supportive criteria, at least one of which must be among those marked with an asterisk (*) below are present, the patient is eligible as Omenn Syndrome.
- Hepatomegaly
- Splenomegaly
- Lymphadenopathy
- Elevated IgE
- Elevated absolute eosinophil count
- *Oligoclonal T cells measured by CDR3 length or flow cytometry (upload report)
- *Proliferation to PHA is reduced to < 50% of lower limit of normal (LLN) or SI < 30
- *Low TRECs and/or percentage of CD4+/RA+ CD31+ or CD4+/RA+ CD62L+ cells below the lower level of normal
2. Documented mutation in one of the following SCID-related genes
-
a. Cytokine receptor defects (IL2RG, JAK3) b. T cell receptor rearrangement defects (RAG1, RAG2) 3. No available genotypically matched related donor (sibling) 4. Availability of a suitable donor and graft source
- Haploidentical related mobilized peripheral blood cells
- 9/10 or 10/10 allele matched (HLA-A, -B, -C, -DRB1, -DQB1) volunteer unrelated donor mobilized peripheral blood cells 5. Age 0 to 2 years at enrollment
Note: to ensure appropriate hepatic metabolism, age at time of busulfan start:
For IL2RG/JAK3: 8 weeks For RAG1/RAG2: 12 weeks
6. Adequate organ function defined as:
-
Cardiac:
Left ventricular ejection fraction (LVEF) at rest ≥ 40% or, shortening fraction (SF) ≥ 26% by echocardiogram.
-
Hepatic:
Total bilirubin < 3.0 x the upper limit of normal (ULN) for age (patients who have been diagnosed with Gilbert's Disease are allowed to exceed this limit) and AST and ALT < 5.0 x ULN for age.
-
Renal:
GFR estimated by the updated Schwartz formula ≥ 90 mL/min/1.73 m2. If the estimated GFR is < 90 mL/min/1.73 m2, then renal function must be measured by 24-hour creatinine clearance or nuclear GFR, and must be > 50 mL/min/1.73 m2.
-
Pulmonary No need for supplemental oxygen and O2 saturation > 92% on room air at sea level (with lower levels allowed at higher elevations per established center standard of care).
Exclusion Criteria:
-
Presence of any serious life-threatening or opportunistic infection at time of enrollment and prior to the initiation of the preparative regimen. Serious infections as defined below that occur after enrollment must be reported immediately to the Study Coordinating Center, and enrollment will be put on hold until the infection resolves. Ideally enrolled subjects will not have had any infection. If patients have experienced infections, these must have resolved by the following definitions:
a. Bacterial i. Positive culture from a sterile site (e.g. blood, CSF, etc.): Repeat culture(s) from same site must be negative and patient has completed appropriate course of antibacterial therapy (typically at least 10 days).
ii. Tissue-based clinical infection (e.g. cellulitis): Complete resolution of clinical signs (e.g. erythema, tenderness, etc.) and patient has completed appropriate course of antibacterial therapy (typically at least 10 days).
iii. Pneumonia, organism not identified by bronchoalveolar lavage: Complete resolution of clinical signs (e.g. tachypnea, oxygen requirement, etc.) and patient has completed appropriate course of antibacterial therapy (typically at least 10 days). If possible, radiographic resolution should also be demonstrated.
b. Fungal i. Positive culture from a sterile site (e.g. blood, CSF, etc.): Repeat culture(s) from same site is negative and patient has completed appropriate course of antifungal therapy (typically at least 14 days). The patient may be continued on antifungal prophylaxis following completion of the treatment course.
c. Pneumocystis i. Complete resolution of clinical signs (e.g. tachypnea, oxygen requirement, etc.) and patient has completed appropriate course of therapy (typically at least 21 days). If possible, radiographic resolution should also be demonstrated. The patient may be continued on prophylaxis following completion of the treatment course.
d. Viral i. Viral PCRs from previously documented sites (blood, nasopharynx, CSF) must be re-tested and are negative.
ii. If re-sampling a site is not clinically feasible (i.e. BAL fluid): Complete resolution of clinical signs (e.g. tachypnea, oxygen requirement, etc.). If possible, radiographic resolution should also be demonstrated.
-
Patients with HIV or HTLV I/II infection will be excluded.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Low Dose Busulfan
Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 25-35 mg*h/L . Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks. |
Randomization between low and medium doses of busulfan for TCR αβ+/CD19+ depleted haploidentical related and unrelated donor HCT. T-cells and B-cells will be removed from the stem cells collected from the donor by an investigational process called alpha-beta CD3+/CD19+ t-cell depletion using a device called CliniMACS® prior to recipient infusion, hopefully minimizing the risk of significant graft vs. host disease (GVHD) or lymphoproliferative disorder.
他の名前:
|
|
実験的:Medium Dose Busulfan
Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 55-65 mg*h/L. Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks. |
Randomization between low and medium doses of busulfan for TCR αβ+/CD19+ depleted haploidentical related and unrelated donor HCT. T-cells and B-cells will be removed from the stem cells collected from the donor by an investigational process called alpha-beta CD3+/CD19+ t-cell depletion using a device called CliniMACS® prior to recipient infusion, hopefully minimizing the risk of significant graft vs. host disease (GVHD) or lymphoproliferative disorder.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Vaccine specific antibody response
時間枠:2 years
|
Humoral immune reconstitution by 2 years post HCT, defined by specific antibody response to tetanus toxoid. Criteria for evaluation of humoral immune response are the following:
Subjects meeting the criteria receive 3 doses of tetanus toxoid at least 4 weeks apart, followed by measurement of tetanus titer at least 4-6 weeks after the 3rd dose. Those who achieve tetanus titer of ≥0.15 IU/ml after vaccination will meet the primary endpoint. Patients who have documented humoral immune response at a time prior to 2 years will be considered a success for the primary endpoint, while patients who do not have humoral immune response evaluated by 2 years will be considered failures for the primary endpoint. |
2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Immune Reconstitution
時間枠:Up to 3 years
|
|
Up to 3 years
|
|
Engraftment
時間枠:Neutrophil Engraftment: 42 days post-HCT. Donor cell chimerism up to 2 years post-HCT.
|
|
Neutrophil Engraftment: 42 days post-HCT. Donor cell chimerism up to 2 years post-HCT.
|
|
Overall Survival
時間枠:3 years
|
Data to track overall survival will be collected at 1, 2 and 3 years post-HCT. |
3 years
|
|
Event Free Survival
時間枠:3 years
|
Data to track event free survival will be collected at 1, 2 and 3 years post-HCT. Events will be defined as 1) death from any cause, 2) rejection of the graft (T-cell and/or whole blood chimerism <5% donor), 3) graft failure necessitating a second HCT procedure from the same donor or a different donor, with or without conditioning, 4) DLI given for treatment of falling chimerism. |
3 years
|
|
Acute graft-versus-host disease (aGVHD)
時間枠:day 100 and 6 months post HCT
|
Occurrence of acute (grade II-IV and grade III-IV) GVHD. |
day 100 and 6 months post HCT
|
|
Chronic graft-versus-host disease (cGVHD)
時間枠:2 years post HCT
|
Occurrence of chronic GVHD by 6 months, 12 months and 24 months post-HCT. |
2 years post HCT
|
|
Post-HCT Complications
時間枠:Up to 2 years post-HCT
|
|
Up to 2 years post-HCT
|
|
Busulfan Pharmacokinetics
時間枠:Pre-HCT
|
Blood samples will be collected on busulfan dosing days 1 and 3 at 2.35, 4, 6 and 8 hours from the time of the start of the infusion. The results will be used to estimate individual exposure (AUC and cAUC). |
Pre-HCT
|
協力者と研究者
捜査官
- スタディチェア:Sung-Yun Pai, MD、National Institutes of Health (NIH)
- スタディチェア:Michael Pulsipher, MD、University of Utah
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。